

## Supporting Information

### **Core-shell SrTiO<sub>3</sub>:Yb<sup>3+</sup>,Er<sup>3+</sup>@mSiO<sub>2</sub> Nanoparticles for Controlled and Monitored Doxorubicin Delivery**

Binbin Li<sup>1</sup>, Heng Liu<sup>1</sup>, Chuanbin Sun<sup>2</sup>, Zeeshan Ahmad<sup>3</sup>, Zhaohui Ren<sup>1</sup>, Xiang Li<sup>1\*</sup>,

Gaorong Han<sup>1\*</sup>

<sup>1</sup> *State Key Laboratory of Silicon Materials, School of Materials Science and Engineering, Zhejiang University, Hangzhou 310027, PR China*

<sup>2</sup> *Eye center, Second Affiliated Hospital, School of Medicine, Zhejiang University, PR China*

<sup>3</sup> *Leicester School of Pharmacy, De Montfort University, Leicester, LE1 9BH, United Kingdom*

*\*Corresponding author: xiang.li@zju.edu.cn; hgr@zju.edu.cn*




Figure S1. EDX examination of STO:Yb<sup>3+</sup>,Er<sup>3+</sup> nanoparticles.




Figure S2. The energy level diagrams of the Yb<sup>3+</sup>, Er<sup>3+</sup> dopant ions and upconversion mechanisms following 980 nm laser diode excitation.




Figure S3. FTIR spectra of (a) STO:Yb<sup>3+</sup>,Er<sup>3+</sup>@0.5mSiO<sub>2</sub>; (b) STO:Yb<sup>3+</sup>,Er<sup>3+</sup>@1.5mSiO<sub>2</sub> nanoparticles before and after surface modification with mesoporous SiO<sub>2</sub> layer.




Figure S4. UCL spectra of  $\text{STO:Yb}^{3+},\text{Er}^{3+}@0.5\text{mSiO}_2$ ,  $\text{STO:Yb}^{3+},\text{Er}^{3+}@1.0\text{mSiO}_2$  and  $\text{STO:Yb}^{3+},\text{Er}^{3+}@1.5\text{mSiO}_2$ .




Figure S5 UCL spectra before and after drug loading of the three samples.




Figure S6. FTIR spectrum of DOX molecules.